Validation of the PsASon ULtrasound Scores in Patients With Psoriatic Arthritis Undergoing TReatment With Apremilast

Sponsor
Medical University of Graz
Study ID
NCT04102449
Phase
PHASE4
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Apremilast — DRUG
    Single arm receiving Apremilast and ultrasound examinations

Study Details

The main purpose of this study is to validate the ultrasound scores PsASon22 and PsASon13 in patients with active psoriatic arthritis undergoing a treatment with Apremilast.

Key Dates

First listed
Sep 25, 2019
Start date
Jul 1, 2020
Status verified
May 2021
Primary completion
Feb 28, 2022
Completion
Feb 28, 2022

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Other: Treatment with Apremilast
    Single group: Apremilast will be prescribed according to the patient information leaflet, i.e.: Dosage form: Oral pill Dosage and Frequency: First 6 days titration phase, followed by 30mg twice daily (in case of kidney problems 30mg once daily in the morning). Treatment duration at the discretion of the treating physician.

Primary Outcome Measure

The difference in the change-score of the PsASon22 [ Time Frame: 4-12-24 months ]

Related Studies